ArticleTherapeutic advances in medical oncology2021
Favourable outcome of patients with breast cancer brain metastases treated with dual HER2 blockade of trastuzumab and pertuzumab.
Article in Therapeutic advances in medical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Brain metastases for Her2 positive breast cancer patients: a systematic review (on the behalf of Italian Association of Radiotherapy and Clinical Oncology).La Radiologia medica · 2026Pooled it
- The evolving landscape of brain metastasis: volume II.Trends in cancer · 2026Review
- Management of HER2+ Breast Cancer with and without Brain Metastases in Saudi Arabia: Literature Insights and an Expert Survey of Current Practices.Breast cancer (Dove Medical Press) · 2026Article
- Chinese Society of Clinical Oncology breast cancer expert consensus on the diagnosis and treatment of breast cancer brain metastasis (2025).Translational breast cancer research : a journal focusing on translational research in breast cancer · 2026Review
- Review
- Anti‑HER2‑targeted therapies for the treatment of advanced HER2‑positive breast cancer with brain metastases (Review).Molecular and clinical oncology · 2025Review
- Central Nervous System Metastases in Breast Cancer.Current treatment options in oncology · 2025Review
- Review
- Breast Cancer Brain Metastasis: A Comprehensive Review.JCO oncology practice · 2024Review
- New Frontiers in the Treatment of Patients with HER2+ Cancer and Brain Metastases: Is Radiotherapy Always Useful?Cancers · 2024Review
- The multidisciplinary management of HER2-positive breast cancer brain metastases: from new biological insights to future therapeutic options.Frontiers in oncology · 2024Review
- Review
- Systemic Therapy for Patients with HER2-Positive Breast Cancer and Brain Metastases: A Systematic Review and Meta-Analysis.Cancers · 2022Review
- Long-term remission under Disitamab Vedotin (RC48) in HR-positive/HER2-positive metastatic breast cancer with brain meningeal, and bone marrow involvement: A case report.Oncology letters · 2022Article
- Review
- Article
- Endocrine resistant breast cancer: brain metastasis.Exploration of targeted anti-tumor therapy · 2022Article
- CSCO expert consensus on the diagnosis and treatment of breast cancer brain metastasis.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2022Review
- Prognostic factors of brain metastasis and survival among HER2-positive metastatic breast cancer patients: a systematic literature review.BMC cancer · 2021Review
- Trastuzumab Deruxtecan for HER2-Positive Breast Cancer with Central Nervous System Metastasis.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDual human epidermal growth factor receptor 2 (HER2) blockade with trastuzumab and pertuzumab (TP) is a standard therapy of metastatic and localized HER2-positive breast cancer (BC), but its activity in breast cancer brain metastases (BCBM) is unknown.
methodsPatients with HER2-positive BCBM were identified from the Vienna Brain Metastasis Registry and clinical data including patient characteristics, therapies and overall survival (OS) were obtained. Patients were grouped into 'TP', 'other-HER2-targeted therapy' and 'no-HER2-targeted therapy' according to received first-line systemic therapy after diagnosis of BCBM. Radiological re-assessment of intracranial lesions was performed in patients treated with TP as systemic first-line therapy according to RANO response criteria for brain metastases (BM).
resultsA total of 252 HER2-positive BC patients with BM were available for this analysis. Patients treated with TP as systemic first-line therapy after diagnosis of BM had a significantly longer OS compared with treatment with other-HER2-targeted therapy and no-HER2-targeted therapy (44
conclusionFirst-line therapy with dual HER2-inhibition of TP after BM diagnosis was associated with the longest median OS times in patients with BCBM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.